Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice

by Petra Martin, Natasha B. Leighl
Published 2017-06-01

Emerging therapies for non-small cell lung cancer

by Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
Published 2019-04-01

Ancillary Testing in Lung Cancer Diagnosis

by William Dubinski, Natasha B. Leighl, Ming-Sound Tsao, David M. Hwang
Published 2012-01-01

Biomarkers that currently effect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1 and KRAS

by Grzegorz Janusz Korpanty, Donna Marie Graham, Mark eVincent, Natasha B. Leighl
Published 2014-08-01

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

by Tristan A. Barnes, Grainne M. O’Kane, Mark David Vincent, Natasha B. Leighl
Published 2017-05-01

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy

by Desirée Hao, Arjun Sengupta, Keyue Ding, ER Ubeydullah, Saikumari Krishnaiah, Natasha B. Leighl, Frances A. Shepherd, Lesley Seymour, Aalim Weljie
Published 2020-07-01

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial

by Jeffrey S. Hoch, Annette Hay, Wanrudee Isaranuwatchai, Kednapa Thavorn, Natasha B. Leighl, Dongsheng Tu, Logan Trenaman, Carolyn S. Dewa, Chris O’Callaghan, Joseph Pater, Derek Jonker, Bingshu E. Chen, Nicole Mittmann
Published 2019-06-01

Additional germline findings from a tumor profiling program

by Neda Stjepanovic, Tracy L. Stockley, Philippe L. Bedard, Jeanna M. McCuaig, Melyssa Aronson, Spring Holter, Kara Semotiuk, Natasha B. Leighl, Raymond Jang, Monika K. Krzyzanowska, Amit M. Oza, Abha Gupta, Christine Elser, Lailah Ahmed, Lisa Wang, Suzanne Kamel-Reid, Lillian L. Siu, Raymond H. Kim
Published 2018-08-01

Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer

by Shirley Xue Jiang, Ryan N. Walton, Katrina Hueniken, Justine Baek, Alexandra McCartney, Catherine Labbé, Elliot Smith, Sze Wah Samuel Chan, RuiQi Chen, Catherine Brown, Devalben Patel, Mindy Liang, Lawson Eng, Adrian Sacher, Penelope Bradbury, Natasha B. Leighl, Frances A. Shepherd, Wei Xu, Geoffrey Liu, Manjusha Hurry, Grainne M. O'Kane
Published 2019-12-01

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

by Tracy L. Stockley, Amit M. Oza, Hal K. Berman, Natasha B. Leighl, Jennifer J. Knox, Frances A. Shepherd, Eric X. Chen, Monika K. Krzyzanowska, Neesha Dhani, Anthony M. Joshua, Ming-Sound Tsao, Stefano Serra, Blaise Clarke, Michael H. Roehrl, Tong Zhang, Mahadeo A. Sukhai, Nadia Califaretti, Mateya Trinkaus, Patricia Shaw, Theodorus van der Kwast, Lisa Wang, Carl Virtanen, Raymond H. Kim, Albiruni R. A. Razak, Aaron R. Hansen, Celeste Yu, Trevor J. Pugh, Suzanne Kamel-Reid, Lillian L. Siu, Philippe L. Bedard
Published 2016-10-01